Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide

REFERENCES

• Kontoghiorghes GJ. Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007; 6(3)236–239
   Web of Science ®Google Scholar
• Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: Advances with deferiprone/deferoxamine combination and concerns on deferasirox's safety, efficacy and costs. Hemoglobin 2008; 32(1–2)1–15
   PubMed Web of Science ®Google Scholar
• Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138(3)407–421
   PubMed Web of Science ®Google Scholar
• Anonymous. Deferasirox: for iron overload: Only a third-line option. Prescrire Int 2007; 16(91)196
   Google Scholar
• Shashaty G, Frankewich R, Chakraborti T, Choudary J, Al-Fayoumi S, Kacuba A, Castillo S, Robie-Suh K, Rieves D, Weiss K, Pazdur R. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park) 2006; 20(14)1799–1806
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases. Drugs Future 2006; 30(12)1241–1251
   Web of Science ®Google Scholar
• Hoffbrand AV, Bartlett A, Veys PA, O'Connor NTJ, Kontoghiorghes GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989; 2(8660)457
   PubMed Web of Science ®Google Scholar
• Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferioxamine in patients with Alzheimer's disease. Lancet 1991; 337(8753)1304–1308
   PubMed Web of Science ®Google Scholar
• Yamamoto RS, Williams GM, Frangel HH, Weisburger JH. 8-Hydroxyquinoline: Chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide. Toxicol Appl Pharmacol 1971; 19(4)687–698
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittelforschung Drug Res 1990; 40(12)1332–1335
   Google Scholar
• Dresow B, Fischer R, Nielsen P, Gabbe EE, Piga A. Effect of oral iron chelator L1 in iron absorption in man. Ann NY Acad Sci 1998; 850: 466–468
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzneimittelforschung Drug Res 1994; 44(4)522–526
   Google Scholar
• Cai L, Li X-K, Song Y, Cherian MG. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 2005; 12(23)2753–2763
   PubMed Web of Science ®Google Scholar
• Hassinof BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003; 35(11)1469–1479
   PubMed Web of Science ®Google Scholar
• Masera N, Rescaldani C, Azzolini M, Vimercati C, Tavecchia L, Masera G, De Molfetta V, Arpa P. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy. Haematologica. 2008; 93(1)e9–10
   PubMed Web of Science ®Google Scholar
• Brock JH, Licéaga J, Kontoghiorghes GJ. The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 1988; 1(1)55–60
   PubMedGoogle Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361(9369)1597–1602
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll and their combinations. Curr Med Chem 2005; 12(23)2663–2681
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9)3738–3744
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3)348–355
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Do we need more iron chelating drugs?. Lancet 2003; 362(9382)495–496
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30(2)239–249
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin 2008; 32(1–2)17–28
   PubMed Web of Science ®Google Scholar
• Tefler P, Goen PG, Christou S, Hadjigavriel M, Kolnagou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 2006; 91(9)1187–1192
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93(5)741–752
   PubMed Web of Science ®Google Scholar